ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Shares are trading flat year to date and the stock remains solidly in value territory, even in the absence of near-term drivers. Clinical trial collaborations with Merck and Bristol-Myers Squibb bode ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

Ambrosia Biosciences has launched with a $16 million series A financing round led by BVF Partners and Boulder Ventures. Ambrosia researchers are developing small-molecule, GLP-1–based drugs for ...

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...